Citazione Stile APA (7a Edizione)

Baraliakos, X., Braun, J., Laurent, D., Baeten, D., van der Heijde, D., Sieper, J., . . . Hueber, W. (2013). Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis.

Citazione stile Chigago Style (17a edizione)

Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.

Citatione MLA (9a ed.)

Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.